Subscribe
shutterstock_1464867716_oleksandrshnuryk
OleksandrShnuryk / Shutterstock.com
7 December 2021AmericasMuireann Bolger

Fresenius in patent dispute over hypocalcemia treatment

Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar (glucose) level is lower than normal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fresenius files IPR against Amgen
15 April 2019   Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
Americas
Fresenius Kabi takes on Sagent Pharmaceuticals in patent battle
6 January 2017   Healthcare company Fresenius Kabi has targeted Sagent Pharmaceuticals in a patent infringement lawsuit centring on generic versions of Naropin.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Fresenius files IPR against Amgen
15 April 2019   Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
Americas
Fresenius Kabi takes on Sagent Pharmaceuticals in patent battle
6 January 2017   Healthcare company Fresenius Kabi has targeted Sagent Pharmaceuticals in a patent infringement lawsuit centring on generic versions of Naropin.

More on this story

Americas
Fresenius files IPR against Amgen
15 April 2019   Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
Americas
Fresenius Kabi takes on Sagent Pharmaceuticals in patent battle
6 January 2017   Healthcare company Fresenius Kabi has targeted Sagent Pharmaceuticals in a patent infringement lawsuit centring on generic versions of Naropin.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool